References
1. Walsh CS. 2015. Two decades beyond BRCA1/2: Homologous recombination,
hereditary cancer risk and a target for ovarian cancer therapy. Gynecol
Oncol 137(2):343-350. doi:
10.1016/j.ygyno.2015.02.017.
2. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast
cancer in patients with a germline BRCA mutation. N Engl J Med
377(6):523-533. doi:
10.1056/NEJMoa1706450.
3. Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. 2020. PARP inhibitor
resistance: The underlying mechanisms and clinical implications. Mol
Cancer 19(1):107. doi:
10.1186/s12943-020-01227-0.
4. Waks AG, Cohen O, Kochupurakkal B, et al. 2020. Reversion and
non-reversion mechanisms of resistance to PARP inhibitor or platinum
chemotherapy in BRCA1/2-mutant metastatic breast cancer. Ann Oncol
31(5):590-598. doi:
10.1016/j.annonc.2020.02.008.
5. Pan JN, Lei L, Ye WW, Wang XJ, Cao WM. 2021. BRCA1 reversion mutation
confers resistance to Olaparib and camrelizumab in a patient with breast
cancer liver metastasis. J Breast Cancer 24(5):474-480. doi:
10.4048/jbc.2021.24.e39.
6. Gornstein EL, Sandefur S, Chung JH, et al. 2018. BRCA2 reversion
mutation associated with acquired resistance to Olaparib in estrogen
receptor-positive breast cancer detected by genomic profiling of tissue
and liquid biopsy. Clin Breast Cancer 18(2):184-188. doi:
10.1016/j.clbc.2017.12.010.
7. Tobalina L, Armenia J, Irving E, O’Connor MJ, Forment JV. 2021. A
meta-analysis of reversion mutations in BRCA genes identifies signatures
of DNA end-joining repair mechanisms driving therapy resistance. Ann
Oncol 32(1):103-112. doi:
10.1016/j.annonc.2020.10.470.
8. Pettitt SJ, Frankum JR, Punta M, et al. 2020. Clinical BRCA1/2
reversion analysis identifies hotspot mutations and predicted
neoantigens associated with therapy resistance. Cancer Discov
10(10):1475-1488. doi:
10.1158/2159-8290.CD-19-1485.
9. Weigelt B, Comino-Méndez I, de Bruijn I, et al. 2017. Diverse BRCA1
and BRCA2 reversion mutations in circulating cell-free DNA of
therapy-resistant breast or ovarian cancer. Clin Cancer Res
23(21):6708-6720. doi:
10.1158/1078-0432.CCR-17-0544.
10. Johnson SF, Cruz C, Greifenberg AK, et al. CDK12 inhibition reverses
de novo and acquired PARP inhibitor resistance in BRCA wild-type and
mutated models of triple-negative breast cancer. Cell Rep
17(9):2367-2381. doi:
10.1016/j.celrep.2016.10.077.
11. Dréan A, Williamson CT, Brough R, et al. 2017. Modeling therapy
resistance in BRCA1/2-mutant cancers. Mol Cancer Ther 16(9):2022-2034.
doi:
10.1158/1535-7163.MCT-17-0098.